Light Therapy May Prevent Oral Mucositis for Some in Cancer Tx
Laser, other light tx recommended for patients treated with HSCT; head and neck RT with, without chemo.
Side-Effect Management
Treatment-Related Taste Changes
What can be done to help with taste changes during chemotherapy?
Use of Aloe Vera for Radiotherapy-Related Skin Reactions
Should aloe vera be used on the skin to prevent radiodermatitis?
Adherence to Topical Management of Hand-Foot Skin Reaction Poor Among Patients Treated With Regorafenib
Researchers sought to measure adherence to topical management regimens among patients with HFSR due to treatment with regorafenib.
Patient Reports Indicate Discussions on Symptom Management Are Insufficient
Researchers surveyed patients on pain, fatigue, and distress due to their diagnosis, as well as their perception of management of these symptoms.
Dermatology Life Quality Index Valid for Assessing Radiodermatitis in Breast Cancer Patients
A pilot study revealed the effectiveness of the DLQI in assessing quality of life measures in women with breast cancer treatment-related radiodermatitis.
Meditation Made Easy: Simple Practices for Patients With Cancer and Their Caregivers
This description of meditation practice, with some simple exercises, can serve as an introduction to its benefits or just help cancer patients and caregivers better cope with disease-related stress.
Preparing Nurses for Possible Adverse Events with CAR-T Therapy
A multidisciplinary program developed to educate nurses on recognizing and managing the signs and symptoms of CAR-T cell therapy adverse effects.
Cancer Radiotherapy Poses Long-Term Risks for Children’s Spinal Development
A report from a European working group of pediatric radiation oncologists focuses on recommendations for safer delivery of radiotherapy to children, especially in dose distributions involving spinal vertebrae.
Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations
Postchemotherapy hospitalizations and costs are higher for patients receiving highly emetogenic chemotherapy with no prophylaxis treatment.
Next post in PallOnc Symposium 2018
